Yusheng Shi1,2,3,4, Xinjing Wang1,2,3,4, Weize Wu1,2,3,4, Junjie Xie1,2,3,4, Jiabin Jin1,2,3,4, Chenghong Peng1,2,3,4, Xiaxing Deng1,2,3,4, Hao Chen1,2,3,4, Baiyong Shen1,2,3,4. 1. Department of General Surgery, Pancreatic Disease Center, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. 2. Research Institute of Pancreatic Diseases, Shanghai Jiaotong University School of Medicine, Shanghai, China. 3. State Key Laboratory of Oncogenes and Related Genes, Shanghai, China. 4. Institute of Translational Medicine, Shanghai Jiaotong University, Shanghai, China.
Abstract
OBJECTIVES: There are few reports about the survival rate of patients with pancreatic adenosquamous cancer (PASC). This study evaluated and analyzed prognostic factors of patients with resectable pancreatic adenosquamous cancer (rPASC), which might fulfill the blank in the research of PASC. METHODS: In this study, we identified and analyzed 55 patients who were diagnosed with rPASC from January 2013 to May 2019 at the Pancreatic Disease Center of the Shanghai Ruijin Hospital affiliated with Shanghai Jiaotong University School of Medicine. Age, sex, BMI, tumor position, and other important demographic data were collected and analyzed. The follow-up was updated by December 31th, 2019 with a median follow-up of nine months. RESULTS: Among the 55 patients, 23 (41.8%) patients were female, and the mean age was 62.0 ± 10.3 years. The median overall survival (OS) time was 10 ± 2.1 months, and the median disease-free survival (DFS) time was 4 ± 0.9 months. The 1-year, 3-year, and 5-year survival rates were 40.9, 17.5, and 11.6%, respectively. The multivariate analysis showed that normal serum level of Ca199 (HR = 0.464, 95% CI = 0.222-0.970, P = 0.041) and Ca125 (HR = 0.441, 95% CI = 0.233-0.835, P = 0.012) were independent favorable prognostic factors. CONCLUSION: Patients with rPASC had poor survival. The 5-year survival rate was only 11.6%. Normal serum levels of Ca199 and Ca125 were independent favorable prognostic factors that predicted prognosis.
OBJECTIVES: There are few reports about the survival rate of patients with pancreatic adenosquamous cancer (PASC). This study evaluated and analyzed prognostic factors of patients with resectable pancreatic adenosquamous cancer (rPASC), which might fulfill the blank in the research of PASC. METHODS: In this study, we identified and analyzed 55 patients who were diagnosed with rPASC from January 2013 to May 2019 at the Pancreatic Disease Center of the Shanghai Ruijin Hospital affiliated with Shanghai Jiaotong University School of Medicine. Age, sex, BMI, tumor position, and other important demographic data were collected and analyzed. The follow-up was updated by December 31th, 2019 with a median follow-up of nine months. RESULTS: Among the 55 patients, 23 (41.8%) patients were female, and the mean age was 62.0 ± 10.3 years. The median overall survival (OS) time was 10 ± 2.1 months, and the median disease-free survival (DFS) time was 4 ± 0.9 months. The 1-year, 3-year, and 5-year survival rates were 40.9, 17.5, and 11.6%, respectively. The multivariate analysis showed that normal serum level of Ca199 (HR = 0.464, 95% CI = 0.222-0.970, P = 0.041) and Ca125 (HR = 0.441, 95% CI = 0.233-0.835, P = 0.012) were independent favorable prognostic factors. CONCLUSION: Patients with rPASC had poor survival. The 5-year survival rate was only 11.6%. Normal serum levels of Ca199 and Ca125 were independent favorable prognostic factors that predicted prognosis.
Authors: Joerg Boecker; Bernd Feyerabend; Katharina Tiemann; Igor Buchwalow; Kim C Wagner; Karl J Oldhafer; Julia Andruszkow; Thies Daniels; Dorthe Boessow; Werner Boecker; Ulf Peter Neumann Journal: Pancreas Date: 2020 May/Jun Impact factor: 3.327
Authors: Matthew Harold G Katz; Thomas H Taylor; Waddah B Al-Refaie; Mark H Hanna; David K Imagawa; Hoda Anton-Culver; Jason A Zell Journal: J Gastrointest Surg Date: 2010-11-17 Impact factor: 3.452